共 53 条
[11]
Uchida T., Yamanaga K., Nishikawa M., Ohtaki Y., Kido H., Watanabe M., Anti-aldosteronergic effect of torasemide, Eur J Pharmacol, 205, pp. 145-150, (1991)
[12]
Lopez B., Gonzalez A., Beaumont J., Querejeta R., Larman M., Diez J., Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure, J Am Coll Cardiol, 50, pp. 859-867, (2007)
[13]
Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J., Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure, J Am Coll Cardiol, 43, pp. 2028-2035, (2004)
[14]
Cosin J., Diez J., Torasemide in chronic heart failure: results of the TORIC study, Eur J Heart Fail, 4, pp. 507-513, (2002)
[15]
Bikdeli B., Strait K.M., Dharmarajan K., Et al., Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?, J Am Coll Cardiol, 61, pp. 1549-1550, (2013)
[16]
Konecke L.L., Clinical trial of bumetanide versus furosemide in patients with congestive heart failure, J Clin Pharmacol, 21, pp. 688-690, (1981)
[17]
Felker G.M., Lee K.L., Bull D.A., Et al., Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, pp. 797-805, (2011)
[18]
Schrier R.W., Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?, J Am Coll Cardiol, 47, pp. 1-8, (2006)
[19]
Heywood J.T., Fonarow G.C., Costanzo M.R., Mathur V.S., Wigneswaran J.R., Wynne J., High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database, J Card Fail, 13, pp. 422-430, (2007)
[20]
Damman K., Testani J.M., The kidney in heart failure: an update, Eur Heart J, 36, pp. 1437-1444, (2015)